



Ref. No.: EIKO/BSE/2023-24/08

Dated: 10.05.2023

To,
Corporate Services Department,
BSE Limited, P J Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.

Ref: Eiko Lifesciences Limited
BSE Scrip Code: EIKO 540204

Dear Sirs,

Subject: Intimation of the meeting of the Rights Issue Committee of Board of Directors of Eiko LifeSciences Limited ("Company") to be held on Monday, May 15, 2023.

Ref.: Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations")

This is further to our intimation dated January 31, 2023 informing approval of the Board of Directors of the Company for issuance of the equity shares of the Company of face value of ₹ 10/- each for an amount not exceeding ₹ 25 Crore by way of Rights Issue to the eligible equity shareholders of the Company as on the record date in accordance with the provisions of Companies Act, 2013 and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, each as amended, and other applicable laws, and pursuant to Regulation 29 of the SEBI Listing Regulations

Further, we wish to inform you that the Company has obtained in-principle approvals from BSE Limited on Friday, May 05, 2023 for the Rights Issue of equity shares aggregating up to ₹ 25 crore.

We further inform you that a meeting of the Right Issue Committee of the Board of Directors of the Company will be held on Monday, May 15, 2023, to, inter alia, consider and determine the terms and conditions of the rights issue including the rights entitlement ratio, the issue price, number of calls to be made and other matters incidental or connected therewith.

Request you to take the same in your record and disseminate the same.

Thanking you
Your Faithfully,

For Eiko LifeSciences Limited

Avi Mundecha
Company Secretary
M. No: ACS-65529